PCRX News & Events

Pacira BioSciences announced the granting of inducement awards on March 3, 2026 to three new employees under Pacira's Amended and Restated 2014 Inducement Plan as a material inducement to each employee's entry into employment with the company. In accordance with Nasdaq Listing Rule 5635(c)(4), the awards were approved by the People & Compensation Committee of the Board of Directors without stockholder approval. One employee received stock options to purchase an aggregate of 2,400 shares of Pacira common stock and three employees received restricted stock units for an aggregate of 5,500 shares of Pacira common stock. The stock options have a 10-year term and a four-year vesting schedule with 25 percent of the underlying shares vesting on the first anniversary of the recipient's first day of employment and in successive equal quarterly installments over the 36 months thereafter. The stock options have an exercise price of $22.10 per share, the closing trading price of Pacira common stock on the Nasdaq Global Select Market on the date of grant. Each restricted stock unit represents the contingent right to receive one share of Pacira common stock and the restricted stock unit awards vest annually in four equal installments beginning on March 1, 2027. Vesting of the equity awards is subject to the employee's continued employment with Pacira. Each equity award is also subject to the terms and conditions of an award agreement.

Pacira BioSciences presented real-world evidence from its Innovations in Genicular Outcomes Registry, IGOR, a first-of-its-kind multicenter, prospective, longitudinal observational registry. The first study demonstrated that Exparel was associated with improvements in pain, opioid use, function, and length of stay after receiving EXPAREL following total knee arthroplasty as compared to patients who received conventional bupivacaine and ropivacaine. The second study demonstrated that cryoneurolysis treatment with iovera was associated with longer-term improvement in pain and function for up to 12 months, relative to a typical improvement of outcomes for 4-6 months following alternative intra-articular agents. The data were presented at the American Academy of Orthopedic Surgeons, AAOS, 2026 Annual Meeting taking place March 2-6 in New Orleans, Louisiana.

Reports Q4 revenue $196.87M, consensus $201.93M. "2025 was a year of disciplined execution for Pacira. With the launch of our 5x30 strategy, we reignited momentum across the business and delivered strong, measurable progress. Our products benefitted more than 2.5 million patients, generated $726 million in revenue, and achieved the highest gross margins in our company's history. Together, these results clearly validate the impact and promise of our 5x30 strategy," said Frank D. Lee, chief executive officer of Pacira BioSciences.

Sees FY26 gross margin 77%-79%. "Our performance continues to be led by EXPAREL, which is benefitting from expanding reimbursement, growing commercial adoption, and strengthened intellectual property providing protection into the 2040s. We further extended our commercial reach through strategic collaborations, while advancing clinical programs positioned to deliver a data-rich year. Pacira enters 2026 stronger than ever as we continue to redefine what is possible in innovative non-opioid pain management," continued Lee.